Enigma Diagnostics opens new Regional HQ office in San Diego

Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today the opening of its new Regional HQ office in San Diego, CA and the appointment of Joel Centeno as VP Regulatory & Quality.

The new 17,000sq ft premises on Nancy Ridge Drive in Sorrento Valley will provide Enigma with access to the deep resource pool of San Diego based in vitro diagnostics (IVD) professionals.  Enigma anticipates US office growth throughout 2010 to provide experience in sales & marketing, assay development, regulatory and manufacturing activities.  

Joel Centeno joins Enigma as VP Regulatory & Quality, US and will be responsible for obtaining appropriate regulatory approval for Enigma's rapid diagnostic instrument systems and products. Joel brings extensive executive experience in quality system design & implementation, new product development in molecular diagnostics and clinical trial expertise.  Before joining the Enigma team, Joel served as Director, QA/RA at Hologic, Inc. where in addition to leading global quality and regulatory activities for the Molecular Diagnostic Division, he also obtained FDA approval on products including Cervista HPV and Inplex cystic fibrosis IVD tests. Joel received his B.S. in Materials Engineering and Metallurgy from the University of Florida in 1999.

"I am very pleased to welcome Joel to our Global Team," said John McKinley, Chairman and CEO of Enigma. "His experience in achieving IVD product regulatory approval will drive the quality systems and regulatory approval necessary to deliver our molecular diagnostics point-of-care systems.  The new US Regional HQ at San Diego will support market penetration across the USA and globally with our rapidly growing and diverse diagnostic systems and future products."


Enigma Diagnostics Limited


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
You might also like... ×
UK diagnostics firm develops rapid test to fight against COVID-19